Prometic’s intravenous Plasminogen was the first PPPSTM generated plasma derived therapeutic to enter clinical trial stages. In August 2016, the Corporation completed enrolment of the congenital plasminogen deficient patients in its pivotal phase 2/3 clinical trial required for the accelerated regulatory approval pathway with the FDA. In October 2016, it was concluded that the phase 2/3 trial had met its primary and secondary endpoints with the intravenous plasminogen treatment. In addition to being safe, well tolerated and without any drug related serious adverse events, Prometic’s plasminogen treatment achieved a 100% success rate of its primary end point, namely, a targeted increase in the blood plasma concentration level of plasminogen as a surrogate target. Moreover, all patients who had active visible lesions when enrolled in the trial had complete healing of their lesions within weeks of treatment, a 100% response rate for this secondary end point.
Most Recent Flipbooks
Notice is hereby given that the Annual and Special Meeting of Shareholders (the "Meeting") of Prometic Life Sciences Inc. (the "Corporation" or "ProMetic") will be held on Wednesday, May 11, 2016
Prometic reports third quarter 2016 highlights and financial results
Prometic reports second quarter 2016 highlights and financial results
Prometic reports its first quarter 2016 highlights and financial results